34 /100
MEDIUM RISK
Score updated Jul 14, 2026

DERM — Journey Medical Corporation Dilution Risk Tracker

Track DERM dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track DERM — Get alerts when the score changes →

As of July 14, 2026, Journey Medical Corporation (DERM) has a DilutionWatch DilutionScore of 34/100, rated MEDIUM dilution risk. Journey Medical Corporation has a market capitalization of $173.74M, 11.56M shares outstanding, 71 institutional holders tracked. Key dilution vectors include approximately 55 months of cash runway.

Source: DilutionWatch (dilutionwatch.com) — data updated daily from SEC EDGAR filings. Not financial advice.

📊 Score Breakdown

📋 Offering Ability
46
💰 Cash Runway
0
📊 Float Risk
20
⚠️ Warrant Exposure
40
🔄Convertible Debt

🌦️ Dilution Forecast

☀️
Clear
No significant dilution signals
0%
No significant dilution signals detected for DERM.
🔔 Track DERM — Get forecast alerts →

💹 Market Data

Market Cap$173.74M
Shares Outstanding11.56M
FloatN/A
Cash$27.22M
Debt$25.37M
Short InterestN/A

🏛 Institutional Holdings

QoQ: ↑ 24.6% shares (2026Q1 vs prior)
71 institutional holders · 13.96M shares
#1 VANGUARD CAPITAL MANAGEMENT LLC 2.16M shares
#2 WASATCH ADVISORS LP 2.13M shares
#3 Opaleye Management Inc. 1.94M shares
+ 17 more holders Sign up free to view →

📉 Short Interest

Short Interest2.99M
Days to Cover5.3
% of FloatN/A
FINRA data as of Jun 30, 2026

📁 Recent SEC Activity

xbrl XBRL CONVERTIBLE Dec 31, 2021
Full SEC filing analysis available with free account

📰 Recent News

No recent news

📋 What This Means for DERM Shareholders

Journey Medical Corporation (DERM) has a DilutionScore of 34/100, rated Medium dilution risk. This tier indicates some dilution exposure — often an older shelf registration with remaining capacity, warrants not yet exercised, or a cash position that will require monitoring over the next several quarters. Score as of July 14, 2026.

DilutionWatch's EDGAR monitoring for DERM shows no major active dilution programs at this time. The primary risk categories — shelf registration capacity, ATM programs, warrant overhang, and cash runway — are each within normal ranges for a company of this profile. This can change quickly if a new S-3 or Form S-1 is filed.

DilutionWatch tracks over 25 SEC filing types for DERM in real-time, scanning EDGAR every 60 seconds. The DilutionWatch screener shows real-time score changes for DERM alongside comparable medium-risk stocks. Not financial advice — this analysis is for informational purposes only.

Track DERM Dilution Risk in Real-Time
Get instant alerts when SEC filings impact dilution risk. Free tier available.
Start Tracking DERM — Free
Real-time SEC alerts DilutionScore™ tracking No credit card required

🔗 Related Stocks — MEDIUM Risk

Other MEDIUM dilution risk stocks tracked by DilutionWatch with similar profiles:

Browse all 7,800+ tracked stocks →

📖 Dilution Education
→ Complete Dilution Guide for Retail Investors → Anti-Dilution Provisions Explained → Stock Dilution Red Flags to Watch → Understanding Shelf Registrations
🔬 More Research for DERM
📊 DERM FDA Catalyst Timeline & Biotech Grade — BiotechSigns 📡 DERM Signal Convergence & Dark Pool Activity — StonkWhisper

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.